Karin Schallreuter

Karin Uta Schallreuter is a German-born medical scientist, and emerita professor for Clinical and Experimental Dermatology at the University of Bradford, England.^[1] She has researched the fields of vitiligo and eczema.

She has a medical degree from the University of Hamburg and did post-doctoral research at the University of Minnesota, before being appointed Professor for Clinical and Experimental Dermatology at the University of Bradford in 1995.^[1]

Her research led to the development of pseudocatalase cream for the treatment of vitiligo.^[2]^[3] She led the Institute for Pigmentary Disorders in Greifswald, Germany, associated with the University of Greifswald, which offered treatments for vitiligo including trips to Jordan for a three-week treatment combining use of this cream with climatotherapy in the UVB-rich climate of Jordan. The institute closed on 1 January 2021 for economic reasons.^[4]^[5]

Selected publications

Schallreuter, Karin U.; Moore, Jeremy; et al. (September 1999). "In Vivo and In Vitro Evidence for Hydrogen Peroxide (H2O2) Accumulation in the Epidermis of Patients with Vitiligo and its Successful Removal by a UVB-Activated Pseudocatalase". Journal of Investigative Dermatology Symposium Proceedings. 4 (1): 91–96. doi:10.1038/sj.jidsp.5640189. PMID 10537016.
Schallreuter, Karin U.; Krüger, Christian; et al. (July 2008). "From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo". International Journal of Dermatology. 47 (7): 743–753. doi:10.1111/j.1365-4632.2008.03660.x. PMID 18613887. S2CID 23531285.

References

^ ^a ^b "Charles Seminar Series 2021-22, Karin Schallreuter: Vitiligo: From bench to bedside". www.ucd.ie. UCD Charles Institute of Dermatology. Retrieved 3 October 2022.
^ Dahl, Mark V. (15 August 2008). "Pseudocatalase and Vitiligo". NEJM Journal Watch. Retrieved 3 October 2022.
^ Bakis-Petsoglou, S.; Le Guay, J L; et al. (2009). "A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo". British Journal of Dermatology. 161 (4): 910–917. doi:10.1111/j.1365-2133.2009.09252.x. PMID 19523170. S2CID 23487507. Retrieved 3 October 2022.
^ "Doctor finds skin disorder cure in the Dead Sea!". Bradford Telegraph and Argus. 21 March 2002. Retrieved 3 October 2022.
^ "Dead Sea Archives". Simon's Vitiligo Blog. Retrieved 3 October 2022.
"Letter to patients" (PDF). Institute for Pigmentary Disorders. October 2020. Retrieved 3 October 2022.
"Letter to patients" (PDF). Institute for Pigmentary Disorders. November 2020. Retrieved 3 October 2022. We are stopping because the economic situation in these times forces us to do so

External links

This article about a German scientist is a stub. You can help Wikipedia by expanding it.

[charles-1] "Charles Seminar Series 2021-22, Karin Schallreuter: Vitiligo: From bench to bedside". www.ucd.ie. UCD Charles Institute of Dermatology. Retrieved 3 October 2022.

[2] Dahl, Mark V. (15 August 2008). "Pseudocatalase and Vitiligo". NEJM Journal Watch. Retrieved 3 October 2022.

[3] Bakis-Petsoglou, S.; Le Guay, J L; et al. (2009). "A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo". British Journal of Dermatology. 161 (4): 910–917. doi:10.1111/j.1365-2133.2009.09252.x. PMID 19523170. S2CID 23487507. Retrieved 3 October 2022.

[4] "Doctor finds skin disorder cure in the Dead Sea!". Bradford Telegraph and Argus. 21 March 2002. Retrieved 3 October 2022.

[simon-5] "Dead Sea Archives". Simon's Vitiligo Blog. Retrieved 3 October 2022.
"Letter to patients" (PDF). Institute for Pigmentary Disorders. October 2020. Retrieved 3 October 2022.
"Letter to patients" (PDF). Institute for Pigmentary Disorders. November 2020. Retrieved 3 October 2022. We are stopping because the economic situation in these times forces us to do so

[1]

[2]

[3]

[4]

[5]